1945 related articles for article (PubMed ID: 8823492)
1. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the pharmacological profile of an olivacine derivative and a potential prodrug.
Kraus-Berthier L; Guilbaud N; Léonce S; Parker T; Genissel P; Guillonneau C; Goldstein S; Atassi G; Pierré A
Cancer Chemother Pharmacol; 2002 Aug; 50(2):95-103. PubMed ID: 12172972
[TBL] [Abstract][Full Text] [Related]
3. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines.
Tsuruo T; Yusa K; Sudo Y; Takamori R; Sugimoto Y
Cancer Res; 1989 Oct; 49(20):5537-42. PubMed ID: 2790778
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity and hematotoxicity of a new, substituted dihydrobenzoxazine, FK973, in mice.
Shimomura K; Manda T; Mukumoto S; Masuda K; Nakamura T; Mizota T; Matsumoto S; Nishigaki F; Oku T; Mori J
Cancer Res; 1988 Mar; 48(5):1166-72. PubMed ID: 3342397
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
Fujimoto K; Oka T; Morimoto M
Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218
[TBL] [Abstract][Full Text] [Related]
6. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.
Kobayashi M; Natsume T; Tamaoki S; Watanabe J; Asano H; Mikami T; Miyasaka K; Miyazaki K; Gondo M; Sakakibara K; Tsukagoshi S
Jpn J Cancer Res; 1997 Mar; 88(3):316-27. PubMed ID: 9140117
[TBL] [Abstract][Full Text] [Related]
8. Preclinical antitumor activity of a new Vinca alkaloid derivative, S 12363.
Pierré A; Kraus-Berthier L; Atassi G; Cros S; Poupon MF; Lavielle G; Berlion M; Bizzari JP
Cancer Res; 1991 May; 51(9):2312-8. PubMed ID: 2015595
[TBL] [Abstract][Full Text] [Related]
9. In vitro cytotoxicity of S16020-2, a new olivacine derivative.
Léonce S; Perez V; Casabianca-Pignede MR; Anstett M; Bisagni E; Pierré A; Atassi G
Invest New Drugs; 1996; 14(2):169-80. PubMed ID: 8913838
[TBL] [Abstract][Full Text] [Related]
10. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties.
Zou Y; Ling YH; Van NT; Priebe W; Perez-Soler R
Cancer Res; 1994 Mar; 54(6):1479-84. PubMed ID: 8137251
[TBL] [Abstract][Full Text] [Related]
12. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors.
Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Malivet V; Chacun C; Jan M; Tillequin F; Michel S; Koch M; Pfeiffer B; Atassi G; Hickman J; Pierré A
Clin Cancer Res; 2001 Aug; 7(8):2573-80. PubMed ID: 11489841
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity and mechanism of action of the novel marine natural products mycalamide-A and -B and onnamide.
Burres NS; Clement JJ
Cancer Res; 1989 Jun; 49(11):2935-40. PubMed ID: 2720652
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice.
Waud WR; Plowman J; Harrison SD; Dykes DJ; Anderson WK; Griswold DP
Cancer Chemother Pharmacol; 1992; 30(4):261-6. PubMed ID: 1322803
[TBL] [Abstract][Full Text] [Related]
15. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid.
Kruczynski A; Colpaert F; Tarayre JP; Mouillard P; Fahy J; Hill BT
Cancer Chemother Pharmacol; 1998; 41(6):437-47. PubMed ID: 9554586
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of 7-N-[[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]]-mitomycin C.
Morimoto M; Ashizawa T; Ohno H; Azuma M; Kobayashi E; Okabe M; Gomi K; Kono M; Saitoh Y; Kanda Y
Cancer Res; 1991 Jan; 51(1):110-5. PubMed ID: 1988076
[TBL] [Abstract][Full Text] [Related]
17. Preclinical antitumor activity of bizelesin in mice.
Carter CA; Waud WR; Li LH; DeKoning TF; McGovren JP; Plowman J
Clin Cancer Res; 1996 Jul; 2(7):1143-9. PubMed ID: 9816280
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of S 16020-2 in two orthotopic models of lung cancer.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Pierré A; Atassi G
Anticancer Drugs; 1997 Mar; 8(3):276-82. PubMed ID: 9095333
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
[TBL] [Abstract][Full Text] [Related]
20. 4'-O-tetrahydropyranyladriamycin as a potential new antitumor agent.
Tsuruo T; Iida H; Tsukagoshi S; Sakurai Y
Cancer Res; 1982 Apr; 42(4):1462-7. PubMed ID: 7060020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
